Head-to-head · WeighScore
Luma Health Co vs TD Tele-Doc Weight Loss
The verdict
Luma Health Co takes it — 75/100 to 61.8/100.
Luma Health Co grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luma Health Co is a nurse-practitioner-led virtual weight-loss and wellness clinic founded by Tiffani McKnight, FNP-C.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Luma Health Co | TD Tele-Doc Weight Loss |
|---|---|---|
| WeighScore | 75/100 | 61.8/100 |
| Grade | C | C |
| Scorecard rank | #59 | #286 |
| Semaglutide | $120/mo (plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | $180/mo (compounded) | Not disclosed |
| Coverage | 30 states | 2 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #59 · C
Strengths
- Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
- No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
- Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
- Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
- HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission
Where it loses points
- Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
- Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
- No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
- Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
- Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline
Graded #286 · C
Strengths
- Brand Wegovy/Zepbound AND compounded sema available; prescribing based on medical history and coverage
- 100% virtual — weekly appointments with board-certified MDs from home; no travel required
- Remote Patient Monitoring Starter Box: biometric scale + blood pressure cuff sync to care team in real time
- In-network with most commercial insurance plans; may cover visits and monitoring equipment
- Physician-led by Dr. Peter Wilbanks MD (30-yr OB/GYN, VCU) and Dr. Michael Perini MD (ABIM board-certified)
Where it loses points
- No public cash pricing; cost entirely depends on insurance coverage — not viable for uninsured patients
- Telehealth available only in Virginia and Maryland; no national reach confirmed
- No Medicare or Medicaid accepted; limited to commercial insurance plans only
- No LegitScript certification found; compounded availability and specific pricing undisclosed on site
- Tirzepatide (Zepbound/Mounjaro) availability less prominent in MD pages; semaglutide is primary focus
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.